Abstracts tagged "Scleroderma"

Abstract Number: 1528 • ACR Convergence 2022
Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial
Janet Pope¹, Susanna Proudman², Wendy Stevens³, Joerg Henes⁴, Rozeta Simonovska⁵, Margarida Alves⁶ and Yannick Allanore⁷, ¹University of Western Ontario, London, ON, Canada, ²Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³Department of Rheumatology, St Vincent’s Hospital, Melbourne, Australia, Melbourne, Australia, ⁴Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ⁵mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) was developed to quantify organ damage in patients with SSc. We assessed outcomes in the SENSCIS…
Abstract Number: 2159 • ACR Convergence 2022
Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort – Associations and Effect of Treatment
Alannah Quinlivan¹, Dennis Neuen², Dylan Hansen³, Wendy Stevens³, Laura Ross⁴, Nava Ferdowsi³, Susanna Proudman⁵, Jenny Walker⁶, Jo Sahhar⁷, Gene-Siew Ngian⁸, Diane Apostolopoulos⁹, Lauren Host¹⁰, Gabor Major¹¹, Kathleen Morrisroe³ and Mandana Nikpour¹², ¹St Vincent's Hospital Melbourne and the University of Melbourne, Melbourne, Australia, ²Liverpool Hospital, Sydney, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Australia, ⁴The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ⁵University of Adelaide, Medindie, Australia, ⁶Flinders Medical Centre, Flinders University, Daw Park, Australia, ⁷Monash Health, Melbourne, Australia, ⁸Melbourne Health, Northcote, Australia, ⁹Monash University, Melbourne, Australia, ¹⁰Fiona Stanley Hospital, London, United Kingdom, ¹¹Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, ¹²The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: To investigate the association between gastroesophageal reflux disease (GORD) and interstitial lung disease (ILD) and determine the effect of GORD treatment on survival in…
Abstract Number: 0519 • ACR Convergence 2022
Myeloablation Followed by Hematopoietic Stem Cell Transplantation Leads to Long-term Normalization of Systemic Sclerosis Molecular Signatures
Nancy Wareing¹, Xuan Wang², Lynette Keyes-Elstein³, Ellen Goldmuntz⁴, Marka Lyons⁵, Peter McSweeney⁶, Daniel Furst⁷, Richard Nash⁶, Leslie Crofford⁸, Beverly Welch⁹, Ashley Pinckney¹⁰, Maureen Mayes¹¹, Keith Sullivan¹² and Shervin Assassi¹³, ¹UTHealth Houston McGovern Medical School, Houston, TX, ²Baylor Institute for Immunology Research, Dallas, TX, ³Rho, Chapel Hill, NC, ⁴NIAID/ NIH, Washington, DC, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Colorado Blood Cancer Institute, Denver, CO, ⁷University of California Los Angeles, Los Angeles, CA, ⁸Vanderbilt University Medical Center, Nashville, TN, ⁹NIAID/NIH, Bethesda, MD, ¹⁰Rho, St. Louis Park, MN, ¹¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ¹²Duke University, Durham, NC, ¹³McGovern Medical School, University of Texas, Houston, TX
Background/Purpose: In the randomized Scleroderma: Cyclophosphamide Or Transplantation (SCOT trial), normalization of systemic sclerosis (SSc) peripheral blood gene expression signatures at the 26-month visit was…
Abstract Number: 1114 • ACR Convergence 2022
Computational Drug Repositioning and 3D Skin Models Identify EGFR and PI3K Inhibitors as Anti-fibrotic Targets for Systemic Sclerosis
Dillon Popovich¹, Noelle Kosarek², Rezvan Parvizi³, Tamar Abel⁴, Mengqi Huang⁵, Monica Espinoza⁶, Avi Smith⁷, Sasha Shenk⁷, Jonathan Garlick⁷ and Michael Whitfield⁸, ¹Dartmouth College, West Lebanon, NH, ²Dartmouth Geisel School of Medicine, Lebanon, NH, ³Dartmouth, Lebanon, NH, ⁴Dartmouth College, Lebanon, NH, ⁵University of Pittsburgh, Pittsburgh, PN, ⁶Dartmouth College, Hanover, NH, ⁷Tufts University School of Dental Medicine, Boston, MA, ⁸Geisel School of Medicine, Lebanon, NH
Background/Purpose: Genome-wide analyses of gene expression in systemic sclerosis (SSc) skin biopsies have identified differential responses based on the mechanism of action of the therapy.…
Abstract Number: 1529 • ACR Convergence 2022
Clinical Nailfold Capillaroscopy Using Dinolite Microscope in Patients with Systemic Sclerosis
Krishnasai Abhishek Madathanapalli¹, Alyssa Williams², Baran Ilayda Gunes², Francis Perry Wilson³, John Pauling⁴, Robyn Domsic⁵, Lan Yu⁶ and Monique Hinchcliff⁷, ¹University of Connecticut School of Medicine, Hartford, CT, ²Yale University, New Haven, CT, ³Yale school of medicine, New Haven, CT, ⁴North Bristol NHS Trust, Bristol, United Kingdom, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, ⁷Yale School of Medicine, Westport, CT
Background/Purpose: The clinical importance of nailfold capillaroscopy (NFC) has grown since its inclusion in the 2013 ACR/EULAR Classification Criteria for systemic sclerosis (SSc), yet few…
Abstract Number: 2161 • ACR Convergence 2022
Alterations of Nutritional Status of Scleroderma Patients and Associations with Disease-specific Features
Sabína Oreská¹, Hana Storkanova¹, Maja Spiritovic², Barbora Hermankova², Michal Vrablík³, Karel Pavelka⁴, Jiří Vencovský⁵, Ladislav Šenolt⁵, Radim Becvar¹ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin and organ involvement and chronic disease course. In particular, involvement of the gastrointestinal tract and systemic inflammation…
Abstract Number: 0521 • ACR Convergence 2022
Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis
Lauren Smith¹, Jamie Perin², Adrianne Woods², Fredrick Wigley³, Laura Hummers⁴ and Ami Shah⁵, ¹Johns Hopkins, District Heights, MD, ²John Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins Univerisity, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Black patients with systemic sclerosis (SSc) develop SSc at a younger age and have more severe disease than White patients, including a higher prevalence…
Abstract Number: 1166 • ACR Convergence 2022
Scleroderma Fibroblasts Induce Alternative Macrophage Activation via an ERK1/2-dependent Mechanism
Taha Dinc¹, Juan-Pablo Zertuche¹, Fatima El Adili², Maria Trojanowska³ and Andreea Bujor³, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Revere, MA, ³Boston University, Boston, MA
Background/Purpose: Activation of the innate immune system in systemic sclerosis (SSc), with an increased number of profibrotic/alternatively-activated macrophages in affected tissues, is an important aspect…
Abstract Number: 1530 • ACR Convergence 2022
Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortality
Aditi Patel¹, Chao Zhang¹ and Soumya Chatterjee², ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Scleroderma renal crisis (SRC) is a rare complication in patients with systemic sclerosis (SSc), characterized by accelerated hypertension and acute kidney injury. ACE inhibitors…
Abstract Number: 2162 • ACR Convergence 2022
Systemic Sclerosis in Alaska Native/American Indian People in Alaska
Vivek Mehta and Elizabeth Ferucci, Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Systemic sclerosis (SSc) is known to have more severe manifestations and higher mortality in Black populations, while fewer studies have examined disparities in epidemiology…
Abstract Number: 0523 • ACR Convergence 2022
The Development of the Ranked Composite Important Difference in Diffuse Cutaneous Systemic Sclerosis; A Clinical and Patient Meaningful Anchor to the ACR-Composite Response Index in SSc
Lesley-Anne Bissell¹, Daniel Furst², sindhu johnson³, Paul hansen⁴, Esmeralda Recalde⁵, Dinesh Khanna⁶ and Francesco Del Galdo⁷, ¹University of Leeds, Leeds, United Kingdom, ²University of California Los Angeles, Los Angeles, CA, ³Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴University of Otago, Dunedin, New Zealand, ⁵World Scleroderma Foundation, Florence, Italy, ⁶Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: The ACR Composite Response Index in Systemic Sclerosis ( ACR-CRISS) is one of the first composite outcome measures in diffuse cutaneous Systemic sclerosis (dcSSc-…
Abstract Number: 1169 • ACR Convergence 2022
Downregulated Fli1 in Systemic Sclerosis Myeloid Cells Contributes to Enhanced Transendothelial Migration
Pablo Weilg Espejo¹, Taha Dinc², Fatima El Adili³, Maria Trojanowska⁴ and Andreea Bujor⁴, ¹Boston Medical Center, Chelsea, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine, Revere, MA, ⁴Boston University, Boston, MA
Background/Purpose: The mononuclear phagocytic system in Systemic Sclerosis (SSc) is central to fibrogenesis and may contribute to fibrosis via enhanced monocyte migration into injured tissues…
Abstract Number: 1531 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON
Yannick Allanore¹, Madelon Vonk², Oliver Distler³, Arata Azuma⁴, Maureen Mayes⁵, Alexandra James⁶, Veronika Kohlbrenner⁷, Margarida Alves⁸, Dinesh Khanna⁹ and Kristin Highland¹⁰, ¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁰Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH
Background/Purpose: In the randomized placebo-controlled SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52…
Abstract Number: 2163 • ACR Convergence 2022
Lipid Profile in Scleroderma Patients and the Associations of Its Changes with Disease-specific Features
Sabina Oreska¹, Hana Storkanova¹, Maja Spiritovic², Barbora Hermankova², Michal Vrablík³, Karel Pavelka⁴, Jiří Vencovský⁵, Ladislav Šenolt⁵, Radim Becvar¹ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin and organ involvement and chronic disease course. Systemic inflammation, involvement of the gastrointestinal tract, and glucocorticoid treatment…
Abstract Number: 0712 • ACR Convergence 2022
Disease Prevalence and Patient Characteristics in Patients with and Without Scleroderma Renal Crisis – A National US-based Inpatient Comparison Study
Anila Hussain¹, Pushti Khandwala² and Thais Moldovan³, ¹Crozer Chester Medical Center, Glen Mills, PA, ²Einstein Medical Center Philadelphia, Glen Mills, PA, ³Rheumatology Care Center, Media, PA
Background/Purpose: Scleroderma renal crisis is a rare complication of Systemic Sclerosis (SSc) with high mortality and morbidity. Most patients present with acute symptomatic increase in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].